CereVasc's ETCHES Study Enrollment Completion: A New Era in Hydrocephalus Treatment CereVasc has successfully completed the enrollment phase for the groundbreaking ETCHES study, focusing on its eShunt System to treat communicating hydrocephalus, demonstrating promising advances in neurological care.

CereVasc's ETCHES Study Enrollment Completion: A New Era in Hydrocephalus Treatment #United_States #Boston #CereVasc #Hydrocephalus #eShunt_System

CereVasc's eShunt System Receives FDA Breakthrough Designation for Pediatric Use CereVasc, Inc. has achieved FDA Breakthrough Device Designation for its eShunt® System, advancing treatment for pediatric patients with hydrocephalus.

CereVasc's eShunt System Receives FDA Breakthrough Designation for Pediatric Use #United_States #Pediatric_Care #Boston #CereVasc #eShunt_System